Long term survival of vinorelbine (N) and trastuzumab (H) as first line therapy for HER2-positive metastatic breast cancer patients (HER2+ MBC) (pts).

被引：0
|
作者：
Chan, A
Petruzelka, L
Untch, M
Martin, M
Gil, MG
Porta, VG
Wojtukiewicz, MZ
Stewart, A
Aubert, D
Gasmi, J
机构：
[1] Mt Hosp, Perth, WA, Australia
[2] Gen Teaching Hosp, Prague, Czech Republic
[3] Univ Munich, Klinikum Grosshadern, D-8000 Munich, Germany
[4] Hosp Clin San Carlos, Madrid, Spain
[5] Inst Catala Oncol, Lhospitalet De Llobregat, Spain
[6] Inst Valenciano Oncol, Valencia, Spain
[7] Reg Canc Ctr, Bialystok, Poland
[8] Christie Hosp NHS Trust, Manchester M20 4BX, Lancs, England
[9] Inst Rech Pierre Fabre, Boulogne, Billancourt, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：25S / 25S
页数：1
相关论文
共 50 条
  • [1] A multicenter study of trastuzumab N and vinorelbine (N) as first and second line therapy for patients (pts) with HER2-positive metastatic breast cancer (HER2+ MBC).
    Franquesa, RM
    Centelles, M
    Villadiego, K
    Janáriz, J
    Arcusa, A
    Cirera, L
    Segui, M
    Saigi, E
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 94S - 94S
  • [2] Clinical predictors of long-term survival in Her2-positive (HER2+) metastatic breast cancer (MBC)
    Murthy, Pooja
    Kidwell, Kelley M.
    Thomas, Dafydd G.
    Griggs, Jennifer J.
    Merajver, Sofia D.
    Schott, Anne F.
    Smerage, Jeffrey B.
    Van Poznak, Catherine H.
    Wicha, Max
    Hayes, Daniel F.
    Henry, N. Lynn
    CANCER RESEARCH, 2015, 75
  • [3] Impact of HER2-targeted therapy on overall survival (OS) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC).
    Berghoff, A.
    Bartsch, R.
    Bago-Horvath, Z.
    Dubsky, P. C.
    Rudas, M.
    Pluschnig, U.
    Wiltschke, C.
    Gnant, M.
    Steger, G. G.
    Zielinski, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] Evaluation of vinorelbine (N) and trastuzumab (H) as first-line therapy for patients (pts) with HER2-positive metastatic breast cancer (HER2+MBC): Impact on clinical response and cardiac function.
    Porta, VG
    Martin, M
    Gil, MG
    Kellokumpu-Lehtinen, P
    Majois, F
    Gasmi, J
    Aubert, D
    Bourrillon, O
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 36S - 36S
  • [5] Predictors of long-term survival in a large cohort of patients with HER2-positive (HER2+) metastatic breast cancer (MBC)
    Gregor, M. A. C.
    Chavez, M.
    Lei, X.
    Giordano, S. H.
    Valero, V.
    Esteva, F.
    Mittendorf, E. A.
    Gonzalez-Angulo, A. M.
    Hortobagyi, G. N.
    CANCER RESEARCH, 2012, 72
  • [6] Systemic therapy and overall survival (OS) in patients (pts) with brain metastases from HER2-positive (HER2+) metastatic breast cancer (MBC).
    Bartsch, R.
    Berghoff, A.
    Pluschnig, U.
    Bago-Horvath, Z.
    Dubsky, P. C.
    Rottenfusser, A.
    Wenzel, C.
    Rudas, M.
    Fitzal, F.
    Dieckmann, K.
    Gnant, M.
    Zielinski, C.
    Steger, G. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] Retreatment with trastuzumab (T)-based therapy in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC) resistant to lapatinib (L)-based therapy.
    Gori, S.
    Montemurro, F.
    Spazzapan, S.
    Metro, G.
    Foglietta, J.
    Bisagni, G.
    Ferzi, A.
    Silva, R. R.
    Gamucci, T.
    Clavarezza, M.
    Stocchi, L.
    Fabi, A.
    Cognetti, F.
    Torrisi, E.
    Crivellari, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] Long term survival and incidence of brain metastasis in HER2-positive (HER2+) metastatic breast cancer patients (MBC) treated with trastuzumab (T): an institutional based review
    Dieras, V.
    Guilhaume, M. N.
    Fall, M.
    Pierga, J. Y.
    Beuzeboc, P.
    Cottu, P.
    Simondi, C.
    Courbard, M.
    Mignot, M.
    Livartowski, A.
    EJC SUPPLEMENTS, 2010, 8 (03): : 202 - 203
  • [9] Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients (pts) with HER2-positive metastatic breast cancer (MBC)
    Peacock, N. W.
    Infante, J. R.
    Yardley, D. A.
    Burris, H. A., III
    Greco, F. A.
    Farley, C.
    Webb, C.
    Spigel, D. R.
    Hainsworth, J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] Efficacy of vinorelbine plus trastuzumab (VT) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab (T).
    Freixinos, V.
    Sanchez-Olle, G.
    De Mattos-Arruda, L.
    Di Cosimo, S.
    Saura, C.
    Gomez, P.
    Perez-Garcia, J. M.
    Cortes, J.
    Baselga, J.
    Bellet, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345